within Pharmacolibrary.Drugs.ATC.V;

model V08AA07
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0015,
    adminDuration  = 600,
    adminMass      = 10000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V08AA07</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Acetrizoic acid is an iodinated, water-soluble X-ray contrast agent historically used for urography and angiography imaging procedures. Due to its relatively high toxicity, especially nephrotoxicity and neurotoxicity, its use has been discontinued and it is not approved for clinical use today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters in adults based on sparse and historical data from related iodinated contrast agents, as no direct pharmacokinetic study with detailed modeling for acetrizoic acid was found.</p><h4>References</h4><ol><li><p>Ma, YM, et al., &amp; Chen, XR (1981). [Pharmacokinetic studies on the intravenous suspension of a new hepatosplenography agent (author&#x27;s transl)]. <i>Yao xue xue bao = Acta pharmaceutica Sinica</i> 16(3) 218–224. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7246172/\">https://pubmed.ncbi.nlm.nih.gov/7246172</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V08AA07;
